Chi-Ping Day, Ph.D.

Chi-Ping  Day, Ph.D.
Staff Scientist
Founder, NIH Interspecific Modeling Interest Group.
Co-PI, NCI FLEX Award, Preclinical Development of Immunotherapy for Brain Metastasis

Team Member of:

The goal of Dr. Day's research is to identify driving factors of progression and therapeutic response in cancer by integrative modeling approach, especially using genetically engineered mouse models and computational models, a "reiterate (real) mouse-to-(computer) mouse" strategy.

Areas of Expertise

Cancer modeling; metastatic melanoma; preclinical study of immunotherapy

Contact Info

Chi-Ping Day, Ph.D.
Center for Cancer Research
National Cancer Institute
Bldg. 37, Room 5046
Bethesda, MD 20892-4264
Ph: 240-760-6905

Dr. Day's expertise is in cancer modeling and translation of preclinical testing to clinics, focusing on immunotherapies and its combinations with other treatment. His researches emphasize the modeling as an approach to map the complex system through a process of continuous improvement. He also have many years of experience in building the infrastructure of research, facilitating the efficiency, proficiency, and productivity of a lab under appropriate budget control.  

Inventions 1. Lentiviral vectors for long term in vivo expression of dual fluorescence/luminescence reporters. (2011) Inventors: Dominic Esposito, Chi-Ping Day, and Glenn Merlino. NIH Employee Invention Report Reference No. E‐132‐2011. 2. A bioimaging marker‐tolerant mouse allowing consistent tumor labeling and monitoring in an immunocompetent mouse model. (2010) Inventors: Chi-Ping Day and Glenn Merlino. NIH Employee Invention Report Reference No. E‐173‐2010.

NIH Scientific Focus Areas:
Cancer Biology, Immunology

Selected Publications

  1. Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G.
    Nature Medicine. (in press): 2020. [ Journal Article ]
  2. Marie KL, Sassano A, Yang HH, Michalowski AM, Michael HT, Guo T, Tsai YC, Weissman AM, Lee MP, Jenkins LM, Zaidi MR, Pérez-Guijarro E, Day CP, Arnheiter H, Davis S, Meltzer PS, Merlino G, Mishra PJ.
    Nature Communication. 11: 333, 2020. [ Journal Article ]
  3. Day CP, Merlino G, Van Dyke T.
    Cell. 163 (1): 39-53, 2015. [ Journal Article ]
  4. Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff-Cherry C, Feigenbaum L, Tüting T, Van Dyke T, Hollingshead M, Merlino G.
    PLoS One. 9 (11): e109956., 2014. [ Journal Article ]
  5. Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G.
    Pigment Cell Melanoma Res. 22: 283-95, 2009. [ Journal Article ]

Dr. Chi-Ping Day received his BS diploma in chemistry from National Cheng-Kung University, Tainan, Taiwan in 1992 and MS diploma in biochemistry from National Yang-Ming University, Taipei, Taiwan in 1996. He then joined the Graduate School of Biomedical Sciences at the University of Texas Health Science Center at Houston and M. D. Anderson Cancer Center, where he received his Ph.D. in 2005 for his work on the development of breast cancer-specific gene therapy system. In October 2005, he joined the laboratory of Dr. Merlino as a visiting fellow to receive his post-doctoral training, then became Staff Scientist in 2012. He received 2007 NCI Director's Innovation Award, 2018 Staff Scientist and Staff Cilinician Outstanding Mentor Award, and 2020 CCR Staff Scientist and Staff Clinician Scientific Merit Award.



By Peter Kelmenson, Technical Information Scientist, The Jackson Laboratory eNews

Immune-deficient mice engrafted with primary human tumors or cell lines have long been the traditional preclinical models for evaluating candidate cancer drugs.  This strategy, while useful for understanding some key aspects of tumor cell behavior, has had only limited success in predicting the efficacy of promising therapeutic candidates clinically. Read more...


New Breed of Mice May Improve Accuracy for Preclinical Testing of Cancer Drugs

Frederick National Laboratory for Cancer Research
May 6, 2015

A new breed of lab animals, dubbed “glowing head mice,” may do a better job than conventional mice in predicting the success of experimental cancer drugs—while also helping to meet an urgent need for more realistic preclinical animal models. Read more...


Glowing Mice with Working Immune Systems Make for Better Cancer Models Say Scientists

By Anthony King, BioPharma Reporter
June 18, 2015

Molecules like green fluorescent protein (GFP) and luciferase are much used for tumours inside mouse models. Engineered into tumour cells, these light-emitting markers can be detected by a camera and allow tumour progress to be tracked and quantified.  Read more...


Mouse models and patient data suggest potential biomarker for immunotherapy response in melanoma

NCI CCR News. April 13, 2020